Welcome to LookChem.com Sign In|Join Free
  • or
(1R,2R)-1,2-bis(N,N’-tert-butyloxycarbonylamino)-4-cyclohexene is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

208533-46-4

Post Buying Request

208533-46-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

208533-46-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 208533-46-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,8,5,3 and 3 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 208533-46:
(8*2)+(7*0)+(6*8)+(5*5)+(4*3)+(3*3)+(2*4)+(1*6)=124
124 % 10 = 4
So 208533-46-4 is a valid CAS Registry Number.

208533-46-4Downstream Products

208533-46-4Relevant academic research and scientific papers

Chiral auxiliary induced diastereoselective synthesis of (R,R)-N,N′-Di(tert-butoxycarbonyl) cyclohex-4-ene-1,2-diamine

Balestri, Davide,Grilli, Stefano,Romano, Ciro,Savoia, Diego

, p. 8021 - 8025 (2014)

The synthesis of optically pure N,N′-di(tert-butoxycarbonyl)-trans-cyclohex-4-ene-1,2-diamine was accomplished from the diimine, which was obtained by condensation of glyoxal and (R)-1-(4-methoxyphenyl)ethanamine. The synthetic sequence involved the highl

A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques

Kalayda, Ganna V.,Kullmann, Maximilian,Galanski, Markus,Gollos, Sabrina

, p. 1295 - 1304 (2017)

Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis of the novel oxaliplatin derivative (CFDA-oxPt) featuring 5(6)-carboxyfluorescein diacetate and evaluation of its applicability for the investigation of oxaliplatin resistance using imaging techniques. CFDA-oxPt was somewhat less cytotoxic than oxaliplatin in sensitive colorectal cancer cells, with EC50 values of 26 and 5.8?μM, respectively. Nevertheless, the potency of the novel complex was significantly decreased to the EC50 of 711.2?μM in oxaliplatin-resistant cells, as was the case for oxaliplatin (EC50?=?81?μM). After incubation, both nuclear and cytosolic localisation was observed. Over time CFDA-oxPt concentrated near the cell membrane and in the vesicular structures, in contrast to the platinum-free label, which was rapidly excreted. These findings suggest that CFDA-oxPt can be used to study oxaliplatin resistance and open the route to new fluorophore-tethered oxaliplatin derivatives.

Synthesis of [3H2]-(R,R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [3H2]-oxaliplatin

Burgos, Alain,Ellames, George J.

, p. 443 - 449 (2007/10/03)

A synthesis of [3H2]-(R,R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [3H2]-Oxaliplatin, 2, is described, rac-trans-4-Cyclohexene-1,2- dicarboxylic acid diethyl ester, 6, was converted to rac-trans-1,2- diaminoc

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 208533-46-4